|
22 Jan 2020 |
Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD
|
|
21 Jan 2020 |
Rafael Pharmaceuticals Announces the Initiation of a Phase 1b/2 Clinical Trial of CPI-613 (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
|
|
21 Jan 2020 |
Clene Nanomedicine Announces First Patient Dosed in the RESCUE-ALS Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead Nanocatalytic Therapeutic, CNM-Au8
|
|
21 Jan 2020 |
Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis
|
|
21 Jan 2020 |
Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis
|
|
21 Jan 2020 |
Polaryx Therapeutics Receives IND Approval for PLX-200 From the FDA for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis
|
|
21 Jan 2020 |
Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
|
|
21 Jan 2020 |
Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
|
|
21 Jan 2020 |
HepaRegeniX GmbH Secures Series B Financing in Excess of €11 Mio. to Advance First Drug Candidate to the Clinic
|
|
20 Jan 2020 |
Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early
|
|
20 Jan 2020 |
Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC
|
|
20 Jan 2020 |
Janssen Seeks Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
|
|
20 Jan 2020 |
Lynparza regulatory submission granted Priority Review in the US for HRR-mutated metastatic castration-resistant prostate cancer
|
|
17 Jan 2020 |
Neuroptika Announces Enrollment Of First Patient In Phase 2 Clinical Trial For Dry Eye Disease
|
|
17 Jan 2020 |
BioTheryX Announces the Initiation of Patient Dosing in a First-in-Man Phase 1 Clinical Trial of BTX-A51, a Multi-Kinase Inhibitor
|
|
17 Jan 2020 |
TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
|
|
15 Jan 2020 |
RECORDATI: Isturisa® (osilodrostat) approved
|
|
15 Jan 2020 |
Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol
|
|
15 Jan 2020 |
Tolero Pharmaceuticals Announces First Patient Dosed in Phase 2 Zella 202 Study of Investigational Agent Alvocidib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Following Treatment with Venetoclax and HMA Combination Therapy
|
|
15 Jan 2020 |
Janssen Seeks Expanded Use of SPRAVATO (Esketamine) Nasal Spray in Europe as a Treatment for Depressive Symptoms in Adults with Major Depressive Disorder Who Have Current Suicidal Ideation with Intent
|
|
15 Jan 2020 |
Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer
|
|
15 Jan 2020 |
Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease
|
|
15 Jan 2020 |
Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase
|
|
15 Jan 2020 |
Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for the Treatment of Parkinson’s Disease
|
|
13 Jan 2020 |
Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre
|
